Publications by authors named "Todd Kohn"

Claim this Profile
D
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of -Deleted Cancers.
Liping H Pettus, Matthew Bourbeau, Nuria A Tamayo, Albert Amegadzie, Diane Beylkin, Todd Kohn

J Med Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties.
Todd J Kohn, Xiaohui Du, SuJen Lai, YuMei Xiong, Renee Komorowski

ACS Med Chem Lett· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Series of Potent Glucokinase Activators Leading to the Discovery of AM-2394.
Paul J Dransfield, Vatee Pattaropong, Sujen Lai, Zice Fu, Todd J Kohn

ACS Med Chem Lett· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the imidazole-derived GPR40 agonist AM-3189.
Zhihua Ma, Daniel C-H Lin, Rajiv Sharma, Jinqian Liu, Liusheng Zhu, Todd Kohn

Bioorg Med Chem Lett· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.
Xiaohui Du, Ronald J Hinklin, Yumei Xiong, Paul Dransfield, Jaehyeon Park, Todd J Kohn

ACS Med Chem Lett· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.
Xiaohui Du, Paul J Dransfield, Daniel C-H Lin, Simon Wong, Yingcai Wang, Todd Kohn

ACS Med Chem Lett· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
Felix Gonzalez-Lopez de Turiso, Youngsook Shin, Matthew Brown, Mario Cardozo, Yi Chen, Todd Kohn

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.
Hilary P Beck, Todd Kohn, Steven Rubenstein, Christine Hedberg, Ralf Schwandner

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5.
Kumiko Takeuchi, Todd J Kohn, Nicholas A Honigschmidt, Vincent P Rocco, Patrick G Spinazze

Bioorg Med Chem Lett· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4.
Vincent P Rocco, Patrick G Spinazze, Todd J Kohn, Nicholas A Honigschmidt, David L Nelson

Bioorg Med Chem Lett· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P3 cap modified Phe*-Ala series BACE inhibitors.
Shu-Hui Chen, Jason Lamar, Deqi Guo, Todd Kohn, Hsiu-Chiung Yang

Bioorg Med Chem Lett· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 3.
Kumiko Takeuchi, Todd J Kohn, Nicholas A Honigschmidt, Vincent P Rocco, Patrick G Spinazze

Bioorg Med Chem Lett· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances Toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT(1A) receptor antagonism/SSRI activities. Part 2.
Kumiko Takeuchi, Todd J Kohn, Nicholas A Honigschmidt, Vincent P Rocco, Patrick G Spinazze

Bioorg Med Chem Lett· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 1.
Kumiko Takeuchi, Todd J Kohn, Nicholas A Honigschmidt, Vincent P Rocco, Patrick G Spinazze

Bioorg Med Chem Lett· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis